Anti-interleukin 5 strategies as a potential treatment for asthma.
A paradigm shift, championed largely by cellular immunologists, has redefined asthma as an immune mediated phenomenon characterised by an interleukin 5 (IL-5) driven eosinophilic bronchitis. This change in emphasis has provoked intense interest in the possibility that inhibitors of IL-5 production, or antagonists of its activity, will provide a new generation of anti-asthma drugs.
Singh
A D
AD
Department of Clinical Immunology, Liverpool Hospital, Sydney, NSW, Australia.
Sanderson
C J
CJ
D001249:Asthma / Q000276:immunology / Q000628:therapy*; D004802:Eosinophilia / Q000517:prevention & control*; D015316:Genetic Therapy; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors* / Q000235:genetics; D014158:Transcription, Genetic / Q000187:drug effects
D015848:Interleukin-5